Get started
Author

Federica Bergami

Observed names: Bergami Federica, F Bergami, F. Bergami
ORCID: 0000-0001-9231-491X
Observed ORCID: 0000-0001-9231-491X
OpenAlex ID: A5055875247
Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection
2021 · Natalia Sherina, Antonio Piralla, et al. · Med · 193
PDF
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
2022 · Fanglei Zuo, Hassan Abolhassani, et al. · Nature Communications · 172
PDF
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
2020 · Stefania Paolucci, Irene Cassaniti, et al. · International Journal of Infectious Diseases · 113
PDF
Immunity to SARS-CoV-2 up to 15 months after infection
2022 · Harold Marcotte, Antonio Piralla, et al. · iScience · 81
SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers
2021 · Francesca Rovida, Irene Cassaniti, et al. · Nature Communications · 67
PDF
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay
2021 · Irene Cassaniti, Elena Percivalle, et al. · Clinical Microbiology and Infection · 55
PDF
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
2021 · A. Lasagna, F. Agustoni, et al. · ESMO Open · 41
PDF
Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?
2020 · Antonio Piralla, Matteo Ricchi, et al. · International Journal of Infectious Diseases · 38
PDF
Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM)
2022 · P. Pedrazzoli, A. Lasagna, et al. · ESMO Open · 33
PDF
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study
2021 · Irene Cassaniti, Federica Bergami, et al. · Clinical Microbiology and Infection · 33
PDF
Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients
2022 · Irene Cassaniti, Marilena Gregorini, et al. · Vaccines · 30
PDF
Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects
2023 · Josè Camilla Sammartino, Irene Cassaniti, et al. · Journal of Medical Virology · 25
PDF
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
2022 · A. Lasagna, F. Bergami, et al. · ESMO Open · 20
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
2021 · A. Lasagna, D. Lilleri, et al. · ESMO Open · 20
PDF
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
2022 · A. Lasagna, F. Bergami, et al. · ESMO Open · 18
PDF
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients
2023 · Federica Zavaglio, Davide Vitello, et al. · Journal of Clinical Virology · 12
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis
2022 · Sara Monti, Chiara Fornara, et al. · Lara D. Veeken · 12
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy
2023 · Angioletta Lasagna, Dalila Mele, et al. · Human Vaccines & Immunotherapeutics · 10
PDF
Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine in vulnerable patients with giant cell arteritis
2021 · Paolo Delvino, Alice Bartoletti, et al. · Lara D. Veeken · 10
PDF
Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant
2021 · Irene Cassaniti, Federica Bergami, et al. · Microorganisms · 9
PDF
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up
2023 · Angioletta Lasagna, Irene Cassaniti, et al. · International Journal of Molecular Sciences · 8
PDF
SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort
2023 · Manuela Rizzi, Stelvio Tonello, et al. · Frontiers in Immunology · 7
PDF
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
2022 · A. Lasagna, F. Bergami, et al. · Annals of Oncology · 5
Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study
2022 · Federica Bergami, Francesca Arena, et al. · Diagnostics · 4
PDF
SARS-CoV-2 mRNA vaccine BNT162b2 elicited a robust humoral and cellular response against SARS-CoV-2 variants.
2021 · Daniele Lilleri, Irene Cassaniti, et al. · Research Square · 4
PDF
Works count: 33
Citation count: 1,032
H-index: 15
I10-index: 19
Year
Topic
Type